Skip to main content

Drug Interactions between Curretab and Logilia

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

medroxyPROGESTERone ulipristal

Applies to: Curretab (medroxyprogesterone) and Logilia (ulipristal)

ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration of ulipristal with combination hormonal contraceptives may reduce the efficacy of both treatments for the prevention of pregnancy. Ulipristal and the progestin component of hormonal contraceptives both bind to the progesterone receptor. Theoretically, competitive inhibition of the receptor may occur, which may diminish the effects of each on ovulation. Limited clinical data are available. When a combined oral contraceptive pill containing ethinyl estradiol-levonorgestrel 30 mcg-150 mcg was started the day after ulipristal dosing during the follicular phase, the ability of the oral contraceptive to suppress ovarian activity was not impacted, as assessed by measurement of follicle size via transvaginal ultrasound, along with serum progesterone and estradiol levels. Ovarian activity was suppressed in 61.5% (24/39) of subjects receiving ulipristal plus oral contraceptive and 62.2% (23/37) of
subjects receiving a placebo plus oral contraceptive. The incidence of ovulation was also similar between the two groups, at 33.3% (13/39) and 32.4% (12/37), respectively.

MANAGEMENT: Concomitant use of ulipristal with combination hormonal contraceptives should be avoided. After emergency contraception with ulipristal, routine contraception should be continued or initiated as soon as possible to ensure ongoing prevention of pregnancy. Patients who wish to use progestogen-containing contraceptives should do so no sooner than 5 days after taking ulipristal, and they should use a reliable barrier method of contraception until their next menstrual period.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2022) "Product Information. Ella (ulipristal)." Afaxys Inc.

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer